Published • loading... • Updated
Sanofi Raises Sales Outlook on Dupixent Strength in Boost for New CEO
Dupixent sales rose 38% to about $6 billion, helping offset Sanofi’s retreat from three late-stage research programs.
- On Thursday, Sanofi raised its full-year sales growth forecast to 10% at constant exchange rates, driven by strong demand for blockbuster asthma drug Dupixent.
- Second-Quarter revenue reached €11.6 billion, a 16% increase, while business operating income hit €3.29 billion, surpassing the €2.96 billion average estimate from Vara Research.
- CEO Belen Garijo confirmed Sanofi is abandoning three R&D programs, including amlitelimab and itepekimab, as part of an accelerated transformation roadmap to prioritize pipeline improvements.
- Garijo projects Dupixent sales will reach around €25 billion by 2030, with newer launch products expected to add approximately €10 billion to future revenues.
- Sanofi decided to stop development on COPD treatments after "changes in the competitive landscape," citing interim results that "did not meet the internal efficacy expectations on clinical endpoints.
Insights by Ground AI
14 Articles
14 Articles
Belén Garijo has been managing the French pharmaceutical group for less than three months and wants to tighten the strategy of the French pharmaceutical laboratory around research and development.
·Paris, France
Read Full Article
DECRYPTAGE - Executive Director of the French pharmacy giant for three months, she raised her ambitions for 2030.
·Paris, France
Read Full Article
Sanofi raised its estimates for the full year, citing a strong performance in the first half of the year, at the time when its new executive president stated that she was working on a plan to reformulate the portfolio of medicines in development of French pharmaceuticals. Exclusive material for subscribers. To have full access, access the link of the subject and register.
·Rio de Janeiro, Brazil
Read Full Article
Coverage Details
Total News Sources14
Leaning Left1Leaning Right3Center4Last UpdatedBias Distribution50% Center
Bias Distribution
- 50% of the sources are Center
50% Center
13%
C 50%
R 37%
Factuality
To view factuality data please Upgrade to Premium
